Cancers · 2020 · 15 citations · 29 references
MedicineCell BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingMtor Inhibitor TherapyOncogenic Signaling PathwaysSignal Transduction In CancerTargeted Cancer TherapyTargeted TherapyEgfr InhibitionExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingMammalian Target Of Rapamycin SignalingMtor InhibitionMtor SignalingReceptor Tyrosine Kinase ActivationSignal Transduction Alteration
Epidermal Growth Factor receptor (EGFR) is a tyrosine kinase receptor widely expressed on the surface of numerous cell types, which activates several downstream signalling pathways involved in cell proliferation, migration and survival. EGFR alterations, such as overexpression or mutations, have been frequently observed in several cancers, including glioblastoma (GBM), and are associated to uncontrolled cell proliferation. Here we show that the inhibition of mammalian target of Rapamycin (mTOR) mediates EGFR delivery to lysosomes for degradation in GBM cells, independently of autophagy activation. Coherently with EGFR internalisation and degradation, mTOR blockade negatively affects the mitogen activated protein/extracellular signal-regulated kinase (MAPK)/ERK pathway. Furthermore, we provide evidence that Src kinase activation is required for EGFR internaliation upon mTOR inhibition. Our results further support the hypothesis that mTOR targeting may represent an effective therapeutic strategy in GBM management, as its inhibition results in EGFR degradation and in proliferative signal alteration.
29
Ambra1 regulates autophagy and development of the nervous system
Gian María Fimia, Anastassia Stoykova, Alessandra Romagnoli et al. · Nature · 2007 · 1K citations · Full text
Clathrin-independent endocytosis of ubiquitinated cargos
Sara Sigismund, Tanja Woelk, Claudia Puri et al. · Proceedings of the National Academy of Sciences · 2005 · 833 citations · Full text